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Abstract
Background: To study whether thyroid function was associated with risk of hip or knee replacement due to
primary osteoarthritis.
Methods: In a prospective cohort study, data from the second and third survey of the Nord-Trøndelag Health
Study were linked to the Norwegian Arthroplasty Register in order to identify total hip or knee replacement as a
result of primary osteoarthritis.
Results: Among 37 891 participants without previously known thyroid disease we recorded 978 total hip
replacements (THRs) and 538 total knee replacements (TKRs) during a median follow-up time of 15.7 years. The
analyses were adjusted for sex, age, BMI (body mass index), smoking, physical activity and diabetes. We did not find
any association between TSH (thyroid stimulating hormone) and THR or TKR due to osteoarthritis. Neither were
changes in TSH over time, or overt hypo- or hyperthyroidism, associated with incidence of THR or TKR.
Conclusion: No association was found between thyroid function and hip or knee joint replacement due to
osteoarthritis.
Keywords: Thyroid function, Thyroid stimulating hormone, Osteoarthritis, Hip joint replacement, Knee joint
replacement
Background
Osteoarthritis in the hip and knee is a major health
problem and leads to significant morbidity [1]. Several
drugs have been evaluated, but so far only exercise has
been found to effectively prevent or delay the onset of
osteoarthritis [2, 3]. This finding emphasizes the import-
ance of identifying modifiable risk factors. Thyroid
hormones play a role in the remodelling and mainten-
ance of bone, and recent studies also indicate the poten-
tial importance of thyroid hormones in joints and
articular cartilage [4]. Genetic studies have suggested
that deiodinase-regulated local availability of the active
thyroid hormone triiodothyronine (T3) plays an import-
ant role in cartilage maintenance and repair [5]. Further
data have indicated that increased intracellular T3 avail-
ability increases the risk of osteoarthritis, leading to the
hypothesis that reduced tissue T3 availability protects
joints from development of osteoarthritis [6]. A phase
III clinical trial investigating the use of eprotirome, a
thyroid receptor β-agonist, for treatment of hypercholes-
terolemia [7], was terminated due to indications of dose
related articular cartilage damage in dogs which had
been treated with eprotirome for 12 months [8]. This
was surprising, as eprotirome is a liver-specific thyroid
receptor β-agonist, but it indicates that thyroid hor-
mones influence cartilage [9] and could play a role in
the pathogenesis of osteoarthritis.
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No prospective population studies have investigated
the association between thyroid function and osteoarth-
ritis. An older cross-sectional study did not find any
association between radiological knee osteoarthritis and
thyroid status measured by thyroid stimulating hormone
(TSH) [10]. In this prospective cohort study of 37 891
individuals without previously known thyroid disease,
the aim was to assess whether thyroid function was asso-
ciated with subsequent risk of hip or knee replacement
due to primary osteoarthritis.
Methods
In the Nord-Trøndelag Health Study (HUNT) all inhabi-
tants of Nord-Trøndelag county ≥ 20 years of age were
invited to participate in three surveys: HUNT1
(1984–1986), HUNT2 (1995–1997) and HUNT3
(2006–2008) [11]. This study only included data from
the HUNT2 and HUNT3 surveys, as the HUNT1
study did not collect blood samples. HUNT2 had 65
237 participants (69.5% of those invited), and HUNT3
had 50 807 participants (54.1% of those invited) [12].
In HUNT2, TSH was measured in 35 269 persons; in
all women over 40 years old, in a random 50% sample of
men over 40 years old and in a random 5% sample of
participants aged 20–40 years. In HUNT3, TSH was
measured in all 49 179 participants. We included 35 269
participants from HUNT2 and 13 132 new participants
with TSH measurements from HUNT3. In persons that
participated in both HUNT2 and HUNT3, baseline mea-
surements from HUNT2 were used in the main analyses.
Among these 48 401 individuals, 10 510 were excluded
from analysis (Fig. 1). The exclusion criteria included
self-reported thyroid disease (hypothyroidism, hyperthy-
roidism, goitre, other thyroid disease, use of levothyrox-
ine, carbimazole, previous thyroid surgery or radioiodine
therapy) (n = 3895), missing information on BMI (n = 364),
missing information on smoking (n = 962), previous THR
or TKR (n = 644), missing date of operation (n = 99), emi-
gration during baseline measurements period (n = 1) or
self-reported osteoarthritis at baseline (n = 4545). Thus, a
total of 37 891 people (22 714 women and 15 177 men)
were eligible for follow-up in this study. Each participant
contributed person-years from baseline (either between
August 1995 and June 1997 or between October 2006 and
June 2008) until a THR or TKR due to osteoarthritis, THR
or TKR due to other causes, migration, death or end of
follow-up (December 31, 2013), whichever occurred first.
Measurements
The participants filled out a self-administered question-
naire, including history of thyroid disease [13]. The
survey also included measurements of height and weight
by trained personnel. Weight was measured while the
participants were wearing light clothing without shoes.
BMI was calculated as weight in kilograms divided by
squared height in metres.
A non-fasting venous blood sample was drawn from
each participant. Concentrations of TSH, free thyroxine
(fT4) and total triiodothyronine (T3) in HUNT2 were
measured at the Hormone Laboratory, Aker University
Hospital, Oslo, using DELFIA hTSH Ultra (sensitivity,
0.03 mU/L; and total analytic variation <5%), DELFIA
fT4 (total analytic variation <7%), and AutoDELFIA T3
(total analytic variation <5%), all from Wallac Oy, Turku,
Finland. In HUNT3, serum TSH and fT4 were measured
at Levanger Hospital, Levanger, Norway, using Architect
cSystems ci8200 (sensitivity, 0.01 mU/l; and a total ana-
lytic variation <5%), and Architect cSystems ci8200 (total
analytic variation <6%), respectively, both from Abbott,
Clinical Chemistry, USA. The measurement methods of
TSH in HUNT2 and HUNT3 have previously been
compared, with similar results [14], and agreement
expressed by Bland-Altman [15] did not reveal any ob-
vious pattern or deviations. The Norwegian population
is considered to have sufficient iodine intake [16], and
reference range for clinically normal TSH was defined
as 0.50 to 3.5 mU/l based on previous publications
from this population [13].
Covariates
The covariates were chosen based on previous litera-
ture, and had to be associated with both thyroid func-
tion and osteoarthritis. We mapped possible casual
Fig. 1 Flowchart (TSH: Thyroid stimulating hormone)
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pathways between all variables using a directed acyclic
graph model (DAG) (Appendix) to visually identify
possible confounding pathways [17]. Based on this
DAG-model, the possible confounders included in this
analysis were sex, age (continuous), BMI (continuous),
current smoking status (never, former or current), dia-
betes (yes or no) and physical activity. Physical activity
was categorized by duration of light physical activity
(none, <1, 1–2, ≥3 h/week), and/or duration of hard
physical activity (none, <1, 1–2, ≥3 h/week). The phys-
ical activity questions have been previously validated
among men, where especially hard physical activity cor-
related well with more objective measures [18]. These
two variables were combined into one physical activity
variable indicating intensity and duration: None (no ac-
tivity), medium (≤2 h/week light physical activity and/
or < 1 h/week hard physical activity), hard (≥ 3 h/week
light physical activity and/or ≥ 1 h/week hard physical
activity).
Osteoarthritis at baseline was based on an affirmative
answer to the question: “Has a doctor ever said that you
have/have had osteoarthritis?” from HUNT2 partici-
pants, and “Have you had or do you have osteoarthritis?”
from HUNT3 participants.
Outcome
In this study, primary total hip or knee replacement was
considered to be a surrogate measure of severe osteoarth-
ritis; and we used primary total hip or knee replacement
due to primary osteoarthritis as outcome. The 11-digit
identification numbers assigned to every Norwegian
citizen enabled linkage to the Norwegian Arthroplasty
Register (NAR). For each arthroplasty performed, the
orthopaedic surgeon submits a standardized form con-
taining information about the patient, the diagnosis that
led to the arthroplasty, the procedure and the type of im-
plant used [19]. NAR was established in 1987 and includes
all artificial joints from 1994 onwards. The completeness
of hip and knee replacement registration is over 95% [20].
Statistical methods
The participants were placed in five categories according
to their TSH level: One category indicating hyperthyroid
function (<0.50 mU/l); three categories within the clinical
reference range (0.50–1.49, 1.5–2.49 and 2.5–3.5 mU/l);
and one category indicating hypothyroid function (≥3.5
mU/l) [21]. Hazard ratios (HRs) of THR or TKR by cat-
egory of TSH were estimated using a Cox proportional
hazards model with 95% confidence interval (CI); TSH
1.5–2.49 mU/l was chosen as a reference. TSH was also
analysed as both a continuous variable, and as log-
transformed continuous TSH. The HRs were adjusted for
age, sex, BMI and smoking. An additional analysis also ad-
justed for physical activity and diabetes. We treated THR
and TKR both as separate outcomes and combined in one
outcome variable of total joint replacement (TJR).
A sub-analysis included only persons that participated
in both HUNT2 and HUNT3 (n = 19 397). TSH levels at
HUNT3 were then subtracted from the TSH levels in
HUNT2 to estimate the change in TSH during the inter-
vening decade. Information on the other baseline covari-
ates was taken from HUNT3. Among these participants
a total of 7740 were excluded due to self-reported
thyroid disease (n = 2744), missing information on BMI
(n = 108), missing information on smoking (n = 621),
previous THR or TKR (n = 928), missing date of oper-
ation (n = 29) or self-reported osteoarthritis at baseline
(n = 3310). Thus, a total of 11 657 people were eligible
for this sub-analysis. This sub-population was also used
in an analysis that investigated whether the results chan-
ged when those who had started on thyroid medication
after baseline in HUNT2 were excluded.
In a sensitivity analysis people were divided into
two groups, one with biochemically manifest (overt)
hypothyroidism (defined as TSH >4.0 mU/L combined
with fT4 < 8.0 pmol/L), and the other with overt
hyperthyroidism (defined as TSH <0.10 mU/L and
fT4 > 20.0 pmol/L and/or total T3 > 2.7 nmol/L). This
classification by overt hypo- or hyperthyroidism was
made possible by the fT4 measurements taken in
people whose TSH levels were <0.20 mU/l or >4.0
mU/l in HUNT2, and in people whose levels were
<0.10 mU/l or >3.0 mU/l in HUNT3. Total T3 was
only available in HUNT2 and only measured if TSH
levels were <0.20mU/L.
Two additional analyses were performed on the baseline
population: First, we investigated the association between
TSH level (categorical) and self-reported osteoarthritis at
baseline by using a logistic regression model, adjust-
ing for sex, age, BMI, smoking, physical activity and
diabetes. Second, we compared the incidence rate of
THR or TKR in participants with and without self-
reported thyroid disease at baseline using Fisher’s
Exact test. After excluding participants with missing
information on BMI and smoking, previous THR or
TKR, missing date of operation or self-reported
osteoarthritis at baseline, 2955 participants reported
thyroid disease.
Proportional hazards assumptions were evaluated by
Schoenfeld residuals tests. They showed proportional
hazards on all covariates, except for age. Thus we did
an additional stratified analysis on age, but it did not
show different results (data not shown). Age was
therefore kept as a continuous variable in all our ana-
lyses. All statistical analyses were two-sided with a
significance level of p < 0.05. The analyses were per-
formed using Stata 14.0/SE (StataCorp LP, College
Station, TX, USA).
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Results
Of the 37 891 participants, 908 (2.4%) had low TSH
(<0.50 mU/l) indicating hyperthyroid function, and 2307
(6.1%) had high TSH (≥3.6 mU/l) indicating hypothyroid
function (Table 1). Among the women, 6.9% had high
TSH, compared to 4.8% of men. Participants with high
TSH were generally older and were less likely to be
current smokers than participants in the reference group
(TSH 1.5–2.4 mU/l). No clear trend was seen in relation
to physical activity.
In total, 978 received THR and 538 received TKR dur-
ing a median follow-up time of 15.7 years (mean 12.3
years). At baseline, the mean age was 50.7 years (SD
15.8), and the mean ages at THR and TKR were 69.5
years (SD 8.9) and 69.4 years (SD 8.4), respectively.
TSH level did not influence the risk of THR or TKR in
the unadjusted analysis or the analysis adjusted for gender,
age, BMI and smoking (Table 2). Neither additional ad-
justment for physical activity and diabetes (Table 2), nor
collapsing the outcome variable into total joint replace-
ment (TJR) (Table 3), altered these results. Analyses using
TSH as a continuous variable did not show any associ-
ation between TSH and THR or TKR (Fig. 2). Additional
log-transformation of TSH as a continuous variable did
not significantly change these results (data not shown).
In a separate analysis studying the change in TSH
(delta-TSH) during the time between HUNT2 and
HUNT3, 11 657 participants were included. Of these,
200 received THR and 102 received TKR during a mean
follow-up time of 6.1 years. No association was seen be-
tween changes in TSH and risk of THR or TKR (Fig. 3).
Additional adjustment for baseline TSH did not substan-
tially alter these results. The same sub-population was
also used to identify persons with no thyroid disease or
treatment at baseline in HUNT2 who still had no
thyroid disease or treatment at HUNT3. However, no
association between TSH and THR (HR 1.00, 95%
CI 0.97–1.02) or TKR (HR 0.98, 95% CI 0.94–1.03)
was found.
In a sensitivity analysis neither overt hypo- nor hyper-
thyroid function was found to influence the risk of THR
or TKR, (HR 0.91, 95% CI 0.40–2.04) and (HR 2.01, 95%
CI 0.75–5.4) respectively. Also, no association was found
between overt hypothyroid function and TKR (HR 1.03,
95% CI 0.38–2.78). There were no cases of TKR amongst
the overtly hyperthyroid, so no analysis could be per-
formed in this subgroup.
In additional analyses on the baseline population, there
was no association between TSH levels and self-reported
osteoarthritis at baseline (data not shown). Those with
self-reported thyroid disease at baseline had an incidence
rate of 0.0027 THR per person-year and 0.0015 TKR per
person-year. Our main study population (excluding those
with self-reported thyroid disease) had an incidence rate
of 0.0021 THR per person-year and 0.0012 TKR per
person-year. This gave and incidence rate ratio of
1.28 (95% CI 1.04–1.56) for THR, and 1.27 (95% CI
0.95–1.95) for TKR, and indicated a slightly higher
incidence rate for THR in those with self-reported
thyroid disease, but no significant difference in the
incidence rate for TKR, compared to participants
without self-reported thyroid disease.
Discussion
In this large prospective study we did not find any asso-
ciation between thyroid function and the risk of THR or
Table 1 Study population characteristics in relation to thyroid stimulating hormone (TSH) categories
Serum TSH Total
<0.50 0.50–1.49 1.5–2.49 2.5–3.49 ≥3.5
Participants (%) 908 (2.4) 17675 (46.7) 13228 (34.9) 3773 (10.0) 2307 (6.1) 37891
Women (%) 651 (2.9) 10405 (45.8) 7738 (34.1) 2346 (10.3) 1574 (6.9) 22714 (60.0)
Men (%) 257 (1.7) 7270 (47.9) 5490 (36.2) 1427 (9.4) 733 (4.8) 15177 (40.0)
Age (SD) 50.7 (16.7) 48.2 (15.3) 51.6 (15.6) 54.9 (15.9) 58.3 (15.3) 50.7 (15.8)
BMI (SD) 25.9 (4.4) 26.1 (4.1) 26.8 (4.2) 27.1 (4.4) 27.2 (4.5) 26.5 (4.2)
Smoking status (%)
Never 335 (36.9) 6778 (38.3) 6080 (46.0) 1869 (49.5) 1167 (50.6) 16229 (42.8)
Former 236 (26.0) 4683 (26.5) 3768 (28.5) 1120 (29.7) 723 (31.3) 10530 (27.8)
Current 337 (37.1) 6214 (35.2) 3380 (25.5) 784 (20.8) 417 (18.1) 11132 (29.4)
Physical activity (%) (missing = 6826)
Low 46 (6.5) 862 (6.0) 719 (6.6) 232 (7.4) 151 (8.2) 2010 (6.5)
Medium 371 (52.8) 7226 (49.9) 5454 (50.0) 1555 (49.7) 921 (50.1) 15527 (50.0)
High 286 (40.7) 6394 (44.1) 4738 (43.4) 1344 (42.9) 766 (41.7) 13528 (43.6)
Diabetes (%) (missing = 56) 55 (6.1) 613 (3.5) 559 (4.2) 173 (4.6) 115 (5.0) 1515 4.0
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TKR due to osteoarthritis. Neither were changes in TSH
over time, or overt hypo- or hyperthyroidism, associated
with incidence of THR or TKR.
Few previous population studies have investigated the
association of thyroid function with risk of osteoarthritis.
In 1996, a cross-sectional study of 577 men and 798
women found no evidence of a significant association
between current thyroid status and either chondrocalci-
nosis or osteoarthritis [10]. However, that study only in-
vestigated prevalent osteoarthritis with a concurrent
serum TSH concentration and could not take into ac-
count development in TSH or later treatment for abnor-
mal thyroid function. Since our study could use data
from both the second and third waves of the HUNT-
survey, we were able to investigate the development of
TSH over a median time of 11.2 years (SD 0.6). Change
in TSH over time was however not associated with
osteoarthritis development resulting in the need for joint
replacement.
Previous or current thyroid disease at baseline was an
exclusion criterion in our study. Nonetheless, all
participants with TSH levels suggesting hypothyroid or
hyperthyroid function may have received medical treat-
ment for thyroid disease during the follow-up period,
as participants with biochemical indication of patho-
logical thyroid function were recommended to contact
their general practitioners [22]. This could have weak-
ened any association between TSH and osteoarthritis.
We therefore did a sub-analysis of persons that partici-
pated in both HUNT2 and HUNT3, and excluded
participants that reported use of thyroid medication or
thyroid disease in HUNT3. This did not significantly
alter the results.
Our findings must be interpreted in relation to re-
cent genetic studies on intracellular T3 availability in
joint cartilage. There has been an increased interest
in the effect of deiodinase polymorphisms on osteo-
arthritis [5]. Iodothyronine deiodinases represent a
family of proteins involved in local homeostasis of
thyroxine (T4) and triiodothyronine (T3). Three deio-
dinases have been described and, of these, the deiodi-
nase type 2 (D2) and deiodinase type 3 (D3) are
Table 2 Association between TSH categories and hip or knee replacement due to osteoarthritis
TSH (mU/L) Persons (n) Cases (n) HRa (95% CI) HRb (95% CI) HRc (95% CI)
THR
< 0.50 908 21 0.98 (0.63–1.53) 0.99 (0.64–1.53) 1.04 (0.63–1.69)
0.50–1.49 17675 411 0.93 (0.81–1.08) 1.07 (0.93–1.24) 1.09 (0.94–1.28)
1.5–2.49 13228 359 1 Reference 1 Reference 1 Reference
2.5–3.49 3773 105 0.98 (0.79–1.22) 0.85 (0.68–1.05) 0.88 (0.69–1.11)
> 3.5 2307 82 1.22 (0.96–1.55) 0.96 (0.76–1.22) 0.98 (0.75–1.27)
TKR
< 0.50 908 14 1.26 (0.73–2.16) 1.32 (0.76–2.26) 1.33 (0.74–2.4)
0.50–1.49 17675 224 0.97 (0.80–1.18) 1.15 (0.95–1.40) 1.12 (0.91–1.37)
1.5–2.49 13228 191 1 Reference 1 Reference 1 Reference
2.5–3.49 3773 64 1.12 (0.84–1.48) 0.94 (0.71–1.25) 0.88 (0.65–1.20)
> 3.5 2307 45 1.24 (0.90–1.72) 0.98 (0.70–1.35) 0.87 (0.61–1.25)
(THR total hip replacement, TKR total knee replacement)
aUnadjusted
bAdjusted for age, sex, BMI and smoking
cAdjusted for age, sex, BMI, smoking, physical activity and diabetes
Table 3 Association between TSH categories and total joint replacement (TJR) in the hip or knee due to osteoarthritis
TSH (mU/L) Persons (n) Cases (n) HRa (95% CI) HRb (95% CI) HRc (95% CI)
<0.50 908 35 1.08 (0.77–1.52) 1.10 (0.78–1.55) 1.15 (0.79–1.67)
0.50–1.49 17675 635 0.95 (0.84–1.06) 1.10 (0.98–1.23) 1.10 (0.97–1.25)
1.5–2.49 13228 550 1 Reference 1 Reference 1 Reference
2.5–3.49 3773 169 1.03 (0.87–1.22) 0.88 (0.74–1.05) 0.88 (0.73–1.06)
>3.5 2307 127 1.23 (1.01–1.49) 0.97 (0.80–1.17) 0.94 (0.76–1.16)
aUnadjusted
bAdjusted for age, sex, BMI and smoking
cAdjusted for age, sex, BMI, smoking, physical activity and diabetes
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detected in bone and cartilage. D2 plays a major role
in conversion of T4 to biologically active T3 [23] and
thus upregulates local T3 levels. Deiodinase type 3
(D3) is the main T3-inactivating enzyme and conse-
quently downregulates the local T3 levels. T3 is
considered an important regulator of chondrocyte cell
growth and differentiation in the endochondral
growth plate [24]. Local T3 availability, regulated by
the opposite functions of D2 and D3, may be a deter-
minant of osteoarthritis development. D2 has been
reported to be upregulated in the cartilage of joints
affected by osteoarthritis compared to joints un-
affected by osteoarthritis [25, 26]. However, it is not
known if this is a result of the ongoing osteoarthritis
process, or a reflection of the underlying disease
pathway. Taken together, these findings suggest that
deiodinase regulated local availability of T3 in chon-
drocytes is a possible factor in the pathophysiology of
osteoarthritis [27, 28]. Since our study did not find
any association between circulating TSH, T3/T4
levels and osteoarthritis, it is conceivable that the
serum thyroid hormone levels may be independent
of local intracellular T3 levels in joints. Another
possible explanation could be that polymorphism in
the gene coding for D2 creates a predisposition for
non-optimal bone shape [29, 30], leading to in-
creased risk of osteoarthritis independent of local
thyroid hormone levels.
Strengths and limitations
Our study included over 37 000 persons without known
thyroid disease at baseline, and in most cases thyroid
function was measured many years prior to joint re-
placement. To the best of our knowledge, this is the
first prospective population study addressing the asso-
ciation between thyroid function and joint replacement
due to primary osteoarthritis. The prospective design
and longitudinal data on TSH measurements are
strengths of this study. By excluding participants with
self-reported osteoarthritis at baseline it was possible to
differentiate between risk of osteoarthritis development
and progression.
Our study used joint replacement due to primary
osteoarthritis as a surrogate measure of severe osteo-
arthritis. Validation of the osteoarthrosis diagnosis from
the Norwegian Arthroplasty Register has not been done
in an unselected population [31]. However, the Danish
hip Arthroplasty Registry has reported a positive predict-
ive value of 85% regarding primary hip osteoarthritis
diagnosis [32], and it is likely that these results are
comparable to the Norwegian Arthroplasty Register. The
advantage of using joint replacement as a proxy for
osteoarthritis is its unambiguous connection with dis-
ease burden of osteoarthritis compared to other osteo-
arthritis definitions, e.g., radiographic criteria, symptom
criteria or osteoarthritis defined by self-reported diagno-
sis [33]. However, this outcome measure is still limited
in some respects, most importantly, that patients’ health
status and potential comorbidities influence orthopaedic
surgeons’ choices regarding operative treatment. Sec-
ondly, persons with moderate osteoarthritis who engage
in demanding physical activities could be more moti-
vated to have surgery than less active persons. Per-
sons who are generally inactive may be less motivated
to have surgery even if they have more severe osteo-
arthritis. This could give a healthy patient selection
bias with corresponding underestimation of the effect
of thyroid function.
Previous injuries increase the risk of knee osteoarth-
ritis [34, 35], but only joint replacements due to pri-
mary/idiopathic osteoarthritis were included in our
study. We did not have direct information on previous
injury, but we excluded all cases in which the operating
surgeon reported that the knee joint replacement was
due to sequela from fracture, ligament injury, meniscal
injury, infection, rheumatoid arthritis or ankylosing
spondylitis.
The interrelationship between BMI and thyroid func-
tion is complex and BMI could be treated as either a
confounder or a mediator in our model [36]. The reason
we chose to define it as a confounder was that we
wanted to investigate the direct effect of thyroid function
on joint replacement, independent of BMI. Potential
Fig. 2 Association between continuous TSH and total hip replacement
(THR) or total knee replacement (TKR) due to osteoarthritis. (Adjusted
for age, sex, BMI, smoking, physical activity and diabetes)
Fig. 3 Association between change in TSH (delta TSH) and total hip
replacement (THR) or total knee replacement (TKR) due to
osteoarthritis. (Adjusted for age, sex, BMI and smoking)
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confounding by other unmeasured factors could not be
excluded. But these factors should then be associated
with both thyrotropin level and osteoarthritis. Therefore,
we did not adjust for level of education in this study
(Appendix).
The participation rate in the HUNT-surveys was fairly
high compared to most other surveys, but there is
always a potential risk of selection bias that cannot be
adjusted for in the statistical analysis [37]. Blood samples
were not drawn at a set time of the day, and it is known
that other factors like exercise and sleep deprivation
influence TSH levels [38]. This might have led to non-
differential classification bias, thus weakening any
associations. We also only had data on fT4 and T3 in
subpopulations. Therefore, the absolute numbers of
participants with overt hypo- or hyperthyroidism were
small, reducing the power to detect any association
between them and euthyroid subject and should thus be
interpreted with caution.
This study focused on the relationship between thyroid
function and osteoarthritis. However, there may also be
an association between autoimmune thyroid disease and
osteoarthritis [39]. As thyroid autoantibody not neces-
sarily correlate with thyroid function, an association
between thyroid function and osteoarthritis trough auto-
immune factors could be missed in our study.
The exclusion of participants who reported hypo- or
hyperthyroidism in their answers regarding use of treat-
ment or medication might have caused misclassification
since radioiodine is used in the treatment of cancer and
T4 in the medical treatment of goitre. However, these
treatments are infrequent, and it is unlikely that they
substantially altered our results.
In the analysis comparing incidence rate of THR in
people with and without self-reported thyroid disease we
found a small, but significant, increased risk of THR in
people reporting thyroid disease. And since we excluded
participants with self-reported thyroid disease, this might
have led to an underestimation of the effect on THR. We
therefore did an additional analysis including those with
self-reported thyroid disease: This showed no association
between TSH levels and THR in a Cox-regression model
(data not shown), and thus confirmed the findings from
the primary analysis.
Conclusion
In this prospective study of 37 891 participants without
previously known thyroid disease, we did not find that
thyroid function was associated with risk of hip or knee
joint replacement due to osteoarthritis. Neither did we
find any association between TSH development over




BMI: Body mass index; D2: Deiodinase type 2; D3: Deiodinase type 3;
DAG: Directed acyclic graph; fT4: Free thyroxine; HR: Hazard ratio; HUNT: The
Nord-Trøndelag Health study; NAR: Norwegian Arthroplasty Register;
OA: Osteoarthritis; SD: Standard deviation; T3: Triiodothyronine; T4: Thyroxine;
THR: Total hip replacement; TKR: Total knee replacement; TSH: Thyroid
stimulating hormone
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